Tejara Capital Ltd Purchases New Holdings in Establishment Labs Holdings Inc. $ESTA

Tejara Capital Ltd purchased a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 130,979 shares of the company’s stock, valued at approximately $11,239,000. Establishment Labs makes up approximately 4.6% of Tejara Capital Ltd’s investment portfolio, making the stock its 3rd biggest holding. Tejara Capital Ltd owned approximately 0.45% of Establishment Labs at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Establishment Labs in the 2nd quarter valued at approximately $135,752,000. Rice Hall James & Associates LLC acquired a new position in Establishment Labs during the second quarter worth $48,134,000. Goldman Sachs Group Inc. increased its holdings in Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after buying an additional 438,206 shares during the last quarter. Viking Global Investors LP acquired a new position in Establishment Labs during the second quarter worth $14,669,000. Finally, Soleus Capital Management L.P. bought a new stake in Establishment Labs during the second quarter worth $9,050,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on ESTA. JPMorgan Chase & Co. increased their price target on shares of Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Canaccord Genuity Group set a $105.00 price objective on shares of Establishment Labs in a research note on Thursday, August 6th. Mizuho upped their target price on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. TD Cowen raised their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, BTIG Research lifted their price target on Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $100.25.

Establishment Labs Stock Down 5.1%

ESTA opened at $71.52 on Friday. The stock’s fifty day simple moving average is $86.38 and its 200 day simple moving average is $74.85. Establishment Labs Holdings Inc. has a 1-year low of $36.53 and a 1-year high of $97.59. The stock has a market cap of $2.13 billion, a PE ratio of -54.60 and a beta of 1.07. The company has a current ratio of 3.84, a quick ratio of 2.52 and a debt-to-equity ratio of 12.11.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The company had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.57) earnings per share. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.